Cargando…

Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling

BACKGROUND: Abnormal sympathetic hyperactivity has been shown to lead to pulmonary arterial hypertension (PAH) deterioration. The purpose of this study was to examine whether the transection of the cervical sympathetic trunk (TCST) can inhibit the progression of PAH in a monocrotaline (MCT)-induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yongpeng, Xiang, Rui, Peng, Xin, Dong, Qian, Li, Dan, Yu, Guiquan, Xiao, Lei, Qin, Shu, Huang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567667/
https://www.ncbi.nlm.nih.gov/pubmed/31200778
http://dx.doi.org/10.1186/s12931-019-1090-2
_version_ 1783427128891539456
author Zhao, Yongpeng
Xiang, Rui
Peng, Xin
Dong, Qian
Li, Dan
Yu, Guiquan
Xiao, Lei
Qin, Shu
Huang, Wei
author_facet Zhao, Yongpeng
Xiang, Rui
Peng, Xin
Dong, Qian
Li, Dan
Yu, Guiquan
Xiao, Lei
Qin, Shu
Huang, Wei
author_sort Zhao, Yongpeng
collection PubMed
description BACKGROUND: Abnormal sympathetic hyperactivity has been shown to lead to pulmonary arterial hypertension (PAH) deterioration. The purpose of this study was to examine whether the transection of the cervical sympathetic trunk (TCST) can inhibit the progression of PAH in a monocrotaline (MCT)-induced PAH model and elucidate the underlying mechanisms. METHODS: Rats were randomly divided into four groups, including a control group, an MCT group, an MCT + sham group and an MCT + TCST group. After performing haemodynamic and echocardiographic measurements, the rats were sacrificed for the histological study, and the norepinephrine (NE) concentrations and protein expression level of tyrosine hydroxylase (TH) were evaluated. The protein expression levels of extracellular signal-regulated kinase (ERK)-1/2, proliferating cell nuclear antigen (PCNA), cyclin A2 and cyclin D1 in pulmonary artery vessels and pulmonary arterial smooth muscle cells (PASMCs) were determined. RESULTS: Compared with the MCT + sham group, TCST profoundly reduced the mean pulmonary arterial pressure (mPAP) (22.02 ± 4.03 mmHg vs. 31.71 ± 2.94 mmHg), right ventricular systolic pressure (RVSP) (35.21 ± 5.59 mmHg vs. 48.36 ± 5.44 mmHg), medial wall thickness (WT%) (22.48 ± 1.75% vs. 46.10 ± 3.16%), and right ventricular transverse diameter (RVTD) (3.78 ± 0.40 mm vs. 4.36 ± 0.29 mm) and increased the tricuspid annular plane systolic excursion (TAPSE) (2.00 ± 0.12 mm vs. 1.41 ± 0.24 mm) (all P < 0.05). The NE concentrations and protein expression levels of TH were increased in the PAH rats but significantly decreased after TCST. Furthermore, TCST reduced the increased protein expression of PCNA, cyclin A2 and cyclin D1 induced by MCT in vivo. We also found that NE promoted PASMC viability and activated the ERK-1/2 pathway. However, the abovementioned NE-induced changes could be suppressed by the specific ERK-1/2 inhibitor U0126. CONCLUSION: TCST can suppress pulmonary artery remodelling and right heart failure in MCT-induced PAH. The main mechanism may be that TCST decreases the NE concentrations in lung tissues, thereby preventing NE from promoting PASMC proliferation mediated by the ERK-1/2 signalling pathway. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12931-019-1090-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6567667
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65676672019-06-27 Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling Zhao, Yongpeng Xiang, Rui Peng, Xin Dong, Qian Li, Dan Yu, Guiquan Xiao, Lei Qin, Shu Huang, Wei Respir Res Research BACKGROUND: Abnormal sympathetic hyperactivity has been shown to lead to pulmonary arterial hypertension (PAH) deterioration. The purpose of this study was to examine whether the transection of the cervical sympathetic trunk (TCST) can inhibit the progression of PAH in a monocrotaline (MCT)-induced PAH model and elucidate the underlying mechanisms. METHODS: Rats were randomly divided into four groups, including a control group, an MCT group, an MCT + sham group and an MCT + TCST group. After performing haemodynamic and echocardiographic measurements, the rats were sacrificed for the histological study, and the norepinephrine (NE) concentrations and protein expression level of tyrosine hydroxylase (TH) were evaluated. The protein expression levels of extracellular signal-regulated kinase (ERK)-1/2, proliferating cell nuclear antigen (PCNA), cyclin A2 and cyclin D1 in pulmonary artery vessels and pulmonary arterial smooth muscle cells (PASMCs) were determined. RESULTS: Compared with the MCT + sham group, TCST profoundly reduced the mean pulmonary arterial pressure (mPAP) (22.02 ± 4.03 mmHg vs. 31.71 ± 2.94 mmHg), right ventricular systolic pressure (RVSP) (35.21 ± 5.59 mmHg vs. 48.36 ± 5.44 mmHg), medial wall thickness (WT%) (22.48 ± 1.75% vs. 46.10 ± 3.16%), and right ventricular transverse diameter (RVTD) (3.78 ± 0.40 mm vs. 4.36 ± 0.29 mm) and increased the tricuspid annular plane systolic excursion (TAPSE) (2.00 ± 0.12 mm vs. 1.41 ± 0.24 mm) (all P < 0.05). The NE concentrations and protein expression levels of TH were increased in the PAH rats but significantly decreased after TCST. Furthermore, TCST reduced the increased protein expression of PCNA, cyclin A2 and cyclin D1 induced by MCT in vivo. We also found that NE promoted PASMC viability and activated the ERK-1/2 pathway. However, the abovementioned NE-induced changes could be suppressed by the specific ERK-1/2 inhibitor U0126. CONCLUSION: TCST can suppress pulmonary artery remodelling and right heart failure in MCT-induced PAH. The main mechanism may be that TCST decreases the NE concentrations in lung tissues, thereby preventing NE from promoting PASMC proliferation mediated by the ERK-1/2 signalling pathway. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12931-019-1090-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-14 2019 /pmc/articles/PMC6567667/ /pubmed/31200778 http://dx.doi.org/10.1186/s12931-019-1090-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhao, Yongpeng
Xiang, Rui
Peng, Xin
Dong, Qian
Li, Dan
Yu, Guiquan
Xiao, Lei
Qin, Shu
Huang, Wei
Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling
title Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling
title_full Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling
title_fullStr Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling
title_full_unstemmed Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling
title_short Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling
title_sort transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via erk-1/2 signalling
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567667/
https://www.ncbi.nlm.nih.gov/pubmed/31200778
http://dx.doi.org/10.1186/s12931-019-1090-2
work_keys_str_mv AT zhaoyongpeng transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT xiangrui transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT pengxin transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT dongqian transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT lidan transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT yuguiquan transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT xiaolei transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT qinshu transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling
AT huangwei transectionofthecervicalsympathetictrunkinhibitstheprogressionofpulmonaryarterialhypertensionviaerk12signalling